“STAR – फार्मा की नई उड़ान, मुनाफ़े का बढ़ता सफ़र – यूएस जेनेरिक्स का राजा!”

Technical Analysis: Pivot at ₹851 with supports ₹828/₹811/₹788; resistance ₹868/₹891/₹908. RSI neutral post-consolidation breakout, volume uptick confirms buying; above 50-day EMA ₹900 signals short-term bullish bias. 1-week +1.14%, 1-month -1.19% but 1-year +36% supports accumulation.

Recent Buying Pressure Reasons: 3-day buying follows Q2 earnings beat (PAT +84% YoY) and $400M US FY28 target guidance; analysts target ₹1,220 amid niche generics momentum. Reduced debt + improving liquidity attracts value hunters post-consolidation. Rally Continuation & Key Levels: Rally likely continues to ₹975-1,000 if holds ₹880 support; breakdown below ₹811 risks pullback to ₹787. Target ₹1,220 on sustained volume; monitor Nov 21 Kotak conference for catalysts. Bullish if breaks ₹908 decisively. Positive Points: Profit turnaround: 5-yr CAGR 124%, ROE 151% last year. Debt reduction, EBITDA margins 19%, global generics presence (US/EU/Australia). Strong quarterly growth, niche formulations edge. Negative Points: Poor 5-yr sales growth 10.6%, promoter holding low 27.9% (44.1% pledged). Trading at 3.19x book value ₹299, management score poor. Working capital days improved but inventory high 236 days.